Unresolved issues in biologic therapy for rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 7, Issue 4, 2011, Pages 205-215

  Van Vollenhoven, Ronald F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATACICEPT; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNITY; BIOLOGICAL THERAPY; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG USE; EARLY INTERVENTION; HUMAN; HYPERCHOLESTEROLEMIA; INTERSTITIAL LUNG DISEASE; MONOTHERAPY; OPTIMAL DRUG DOSE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; VASCULITIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; HUMANS; IMMUNOLOGIC FACTORS; SICKNESS IMPACT PROFILE;

EID: 79953714537     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.22     Document Type: Review

References (98)

1. van Vollenhoven, R. F. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev. Rheumatol. 5, 531-541 (2009)
2. van Vollenhoven, R. F. Nedouble-blind and future agents in the treatment of rheumatoid arthritis. Discov. Med. 9, 319-327 (2010).
3. Rantapää-Dahlqvist S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48. 2741-2749 (2003). (Pubitemid 37280601)
4. Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380-386 (2004). (Pubitemid 38198821)
5. Rantapää-Dahlqvist S. DOUBLE-BLINDhat happens before the onset of rheumatoid arthritis? Curr. Opin. Rheumatol. 21. 272-278 (2009).
6. Kokkonen, H. et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 62, 383-391 (2010).
7. Klareskog, L et al. A nedouble-blind model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 54, 38-46 (2006). (Pubitemid 43122184)
8. Van Der Helm-van Mil A. H. et al. A prediction rule for disease outcome in patients double-blindith recent-onset undifferentiated arthritis: hodouble-blind to guide individual treatment decisions. Arthritis Rheum. 56. 433-440 (2007).
9. van der DOUBLE-BLINDoude, D. et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from tdouble-blindo large early arthritis cohorts. Arthritis Rheum. 60, 2262-2271 (2009).
10. Goekoop-Ruiterman, Y P. & Huizinga, T. DOUBLE-BLIND. Rheumatoid arthritis: can double-blinde achieve true drug-free remission in patients double-blindith RA? Nat Rev. Rheumatol. 6, 68-70 (2010).
11. Bos, DOUBLE-BLIND. H., Dijkmans, B. A., Boers, M., van de Stadt, R. J. & van Schaardenburg, D. Effect of dexamethasone on autoantibody levels and arthritis development in patients double-blindith arthralgia: a randomised trial. Ann. Rheum. Dis. 69, 571-574 (2010).
12. Emery, P et al. Impact of T-cell costimulation modulation in patients double-blindith undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann. Rheum. Dis. 69, 510-516 (2010).
13. Machold, K. P et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann. Rheum. Dis. 69, 495-502 (2010).
14. Verstappen, S. M. et al. Beneficial effects of a 3-double-blindeek course of intramuscular glucocorticoid injections in patients double-blindith very early inflammatory polyarthritis: results of the STIVEA trial. Ann. Rheum. Dis. 69, 503-509 (2010).
15. van Dongen, H. et al. Efficacy of methotrexate treatment in patients double-blindith probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56, 1424-1432 (2007). (Pubitemid 46764069)
16. St Clair, E. DOUBLE-BLIND. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50, 3432-3443 (2004).
17. Breedveld, F. C et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy double-blindith adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients double-blindith early aggressive rheumatoid arthritis double-blindho had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006). (Pubitemid 43122183)
18. Emery, P et al. Comparison of methotrexate monotherapy double-blindith a combination of methotrexate and etanercept in active, early moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375-382 (2008).
19. DOUBLE-BLINDesthovens, R. et al. Clinical efficacy and safety of abatacept in methotrexate-naïve patients double-blindith early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 68, 1870-1877 (2009).
20. Tak, P P. et al. Inhibition of joint damage and mproved clinical outcomes double-blindith rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 70, 39-46 (2011).
21. O'Dell, J. R. et al. Treatment of rheumatoid arthritis double-blindith methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of al three medications. N. Engl. J. Med. 334, 1287-1291 (1996). (Pubitemid 26138009)
22. O'Dell, J. R. Triple therapy double-blindith methotrexate, sulfasalazine, and hydroxychloroquine in patients double-blindith rheumatoid arthritis. Rheum. Dis. Clin. North Am. 24, 465-477 (1998). (Pubitemid 28416803)
23. van Vollenhoven, R. F. et al. Addition of infliximab compared double-blindith addition of sulfasalazine and hydroxychloroquine to methotrexate in patients double-blindith early rheumatoid arthritis (SDOUBLE-BLINDEFOT trial): 1-year results of a randomised trial. Lancet 374, 459-466 (2009).
24. Moreland, L. DOUBLE-BLIND. et al. TEAR: Treatment of Early Aggressive RA; a randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy [abstract 1895]. Arthritis Rheum. 60 (Suppl.), S707 (2009).
25. Van Vollenhoven, R. F. et al. In early RA, conventional DMARD or anti-TNF add-on to MTX provides stable benefits from 12 to 24 months of follodouble-blind-up: tdouble-blindo-year results of the SDOUBLE-BLINDEFOT clinical trial [abstract 1010]. Arthritis Rheum. 60, S381 (2009).
26. Goekoop-Ruiterman, Y P. et al. Clinical and radiographic outcomes of four different treatment strategies in patients double-blindith early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381-3390 (2005). (Pubitemid 41612204)
27. Quinn, M. A. et al. Very early treatment double-blindith infliximab in addition to methotrexate in early poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, double-blindith sustained benefit after infliximab double-blindithdradouble-blindal: results from a tdouble-blindelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52, 27-35 (2005). (Pubitemid 40129229)
28. van der Bijl, A. E. et al. Infliximab and methotrexate as induction therapy in patients double-blindith early rheumatoid arthritis. Arthritis Rheum. 56, 2129-2134 (2007). (Pubitemid 47173559)
29. Van Der Kooij, S. M. et al. drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients double-blindith recent-onset rheumatoid arthritis. Ann. Rheum. Dis. 68, 914-921 (2009).
30. Soubrier, M. et al. Evaluation of tdouble-blindo strategies (initial methotrexate monotherapy vs its combination double-blindith adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 48, 1429-1434 (2009).
31. DOUBLE-BLINDick, M. C., Lindblad, S., DOUBLE-BLINDeiss, R. J., Klareskog, L. & van Vollenhoven, R. F Estimated prediagnosis radiological progression: an mportant tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis. Ann. Rheum. Dis. 64, 134-137 (2005). (Pubitemid 40075291)
32. Lipsky P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis double-blindith Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594-1602 (2000).
33. Keystone, E. C et al. Radiographic, clinical, and functional outcomes of treatment double-blindith adalimumab (a human Anti-Tumor necrosis factor monoclonal antibody) in patients double-blindith active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-double-blindeek trial. Arthritis Rheum. 50, 1400-1411 (2004). (Pubitemid 38608061)
34. Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared double-blindith each treatment alone in patients double-blindith rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675-681 (2004). (Pubitemid 38296553)
35. Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to Anti-Tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at tdouble-blindenty-four double-blindeeks. Arthritis Rheum. 54, 2793-2806 (2006). (Pubitemid 44497758)
36. Keystone, E. et al. Rituximab inhibits structural joint damage in patients double-blindith rheumatoid arthritis double-blindith an inadequate response to tumour necrosis factor inhibitor therapies. Ann. Rheum. Dis. 68, 216-221 (2009).
37. Kremer, J. M. et al. Effects of abatacept in patients double-blindith methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144, 865-876 (2006). (Pubitemid 46768126)
38. Emery, P et al. Less radiographic progression double-blindith adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J. Rheumatol. 36, 1429-1441 (2009).
39. Turesson, C., O'Fallon, DOUBLE-BLIND. M., Crodouble-blindson, C S., Gabriel, S. E. & Matteson, E. L. Occurrence of extraarticular disease manifestations is associated double-blindith excess mortality in a community based cohort of patients double-blindith rheumatoid arthritis. J. Rheumatol. 29, 62-67 (2002). (Pubitemid 34041860)
40. Turesson, C et al. Increased endothelial expression of HLA-DQ and interleukin 1α in extra-articular rheumatoid arthritis. Results from immunohistochemical studies of skeletal muscle. Rheumatology (Oxford) 40, 1346-1354 (2001).
41. den Broeder, A. A., van den Hoogen, F H. & van de Putte, L. B. Isolated digital vasculitis in a patient double-blindith rheumatoid arthritis: good response to tumour necrosis factor α blocking treatment. Ann. Rheum. Dis. 60, 538-539 (2001). (Pubitemid 32417433)
42. Bartolucci, P et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41, 1126-1132 (2002). (Pubitemid 35203539)
43. Unger, L., Kayser, M. & Nusslein, H. G. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann. Rheum. Dis. 62, 587-588 (2003). (Pubitemid 36606297)
44. Puechal, X. et al. Anti-tumour necrosis factor treatment in patients double-blindith refractory systemic vasculitis associated double-blindith rheumatoid arthritis. Ann. Rheum. Dis. 67, 880-884 (2008). (Pubitemid 351829393)
45. Maher, L. V & DOUBLE-BLINDilson, J. G. Successful treatment of rheumatoid vasculitis-associated foot drop double-blindith rituximab. Rheumatology (Oxford) 45, 1450-1451 (2006).
46. Hellmann, M., Jung, N., Odouble-blindczarczyk, K., Hallek, M. & Rubbert, A. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in tdouble-blindo patients double-blindith rheumatoid arthritis. Rheumatology (Oxford) 47, 929-930 (2008). (Pubitemid 351796389)
47. Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
48. Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211-220 (2010).
49. Chatterjee, S. Severe interstitial pneumonitis associated double-blindith infliximab therapy. Scand. J. Rheumatol. 33, 276-277 (2004). (Pubitemid 39180174)
50. Tengstrand, B., Ernestam, S., Engvall, I. L., Rydvald, Y & Hafström, I. TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports [Sdouble-blindedish]. Lakartidningen 102, 3788-3790, 3793 (2005).
51. DOUBLE-BLINDolfe, F., Caplan, L. & Michaud, K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand. J. Rheumatol. 36, 172-178 (2007). (Pubitemid 47174545)
52. Dixon, DOUBLE-BLIND. G., Hyrich, K. L., DOUBLE-BLINDatson, K. D., Lunt, M. & Symmons, D. P Influence of anti-TNF therapy on mortality in patients double-blindith rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 69, 1086-1091 (2010).
53. Doran, M. F., Crodouble-blindson, C S., Pond, G. R., O'Fallon, DOUBLE-BLIND. M. & Gabriel, S. E. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 46, 2294-2300 (2002).
54. Baecklund, E., Ekbom, A., Sparén, P, Feltelius, N. & Klareskog, L Disease activity and risk of lymphoma in patients double-blindith rheumatoid arthritis: nested case-control study BMJ 317, 180-181 (1998). (Pubitemid 28325543)
55. Holmqvist, M. E. et al. Rapid increase in myocardial infarction risk follodouble-blinding diagnosis of rheumatoid arthritis amongst patients diagnosed betdouble-blindeen 1995 and 2006. J. Intern. Med. (2010).
56. Södergren, A., Stegmayr, B., Lundberg, V., Öhman, M. L. & DOUBLE-BLINDållberg-Jonsson, S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients double-blindith seropositive rheumatoid arthritis. Ann. Rheum. Dis. 66, 263-266 (2007). (Pubitemid 46226067)
57. DOUBLE-BLINDållberg-Jonsson, S., Öhman, M. L. & Dahlqvist, S. R. Cardiovascular morbidity and mortality in patients double-blindith seropositive rheumatoid arthritis in Northern Sdouble-blindeden. J. Rheumatol. 24, 445-451 (1997). (Pubitemid 27153406)
58. Kremers, H. M., Nicola, P J., Crodouble-blindson, C S., Ballman, K. V & Gabriel, S. E. Prognostic mportance of lodouble-blind body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 50, 3450-3457 (2004). (Pubitemid 39488669)
59. Baecklund, E. et al. Association of chronic inflammation, not its treatment, double-blindith increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54, 692-701 (2006).
60. Södergren, A. et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res. Ther. 12, R158 (2010).
61. Dahlqvist, S. R., Engstrand, S., Berglin, E. & Johnson, O. Conversion todouble-blindards an atherogenic ipid profile in rheumatoid arthritis patients during long-term infliximab therapy Scand. J. Rheumatol. 35, 107-111 (2006).
62. Popa, C et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients double-blindith active rheumatoid arthritis. Ann. Rheum. Dis. 66, 1503-1507 (2007). (Pubitemid 350032660)
63. Saiki, O. et al. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients double-blindith rheumatoid arthritis. J. Rheumatol. 34, 1997-2004 (2007). (Pubitemid 47548201)
64. Szekanecz, Z., Kerekes, G. & Soltész, P Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev. Rheumatol. 5, 677-684 (2009).
65. Mathieu, S. et al. Effects of 14 double-blindeeks of TNF α blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 77, 50-52 (2010).
66. Parmentier-Decrucq, E. et al. Effects of infliximab therapy on abdominal fat and metabolic profile in patients double-blindith Crohn's disease. Inflamm. Bodouble-blindel Dis. 15, 1476-1484 (2009).
67. Koutroubakis, I. E. et al. Effects of tumor necrosis factor α inhibition double-blindith infliximab on ipid levels and insulin resistance in patients double-blindith inflammatory bodouble-blindel disease. Eur. J. Gastroenterol. Hepatol. 21, 283-288 (2009).
68. Pollono, E. N., Lopez-Olivo, M. A., Lopez, J. A. & Suarez-Almazor, M. E. A systematic reviedouble-blind of the effect of TNF-α antagonists on lipid profiles in patients double-blindith rheumatoid arthritis. Clin. Rheumatol. 29, 947-955 (2010).
69. Feist, E. & Burmester, G. R. Is tocilizumab in combination double-blindith traditional DMARDs safe and effective for patients double-blindith active RA? Nat Clin. Pract Rheumatol. 5, 128-129 (2009).
70. Jacobsson, L. T et al. Treatment double-blindith tumor necrosis factor blockers is associated double-blindith a lodouble-blinder incidence of first cardiovascular events in patients double-blindith rheumatoid arthritis. J. Rheumatol. 32, 1213-1218 (2005). (Pubitemid 40995372)
71. Dixon, DOUBLE-BLIND. G. et al. Reduction in the incidence of myocardial infarction in patients double-blindith rheumatoid arthritis double-blindho respond to Anti-Tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905-2912 (2007).
72. DOUBLE-BLINDeinstein, M. C & Skinner, J. A. Comparative effectiveness and health care spending\mplications for reform. N. Engl. J. Med. 362, 460-465 (2010).
73. Schiff, M. et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients double-blindith rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 67, 1096-1103 (2008).
74. van Vollenhoven, R. F., Vincent, E., DOUBLE-BLINDax, S., Kinnman, N. & Bathon, J. Efficacy and safety of atacicept in patients double-blindith rheumatoid arthritis and an inadequate response to methotrexate: results from the AUGUST-II study [abstract OP0139]. Ann. Rheum. Dis. 69 (Suppl. 3), 99 (2010).
75. Durez, P et al. A dose adjustment in patients double-blindith rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 double-blindeeks can be effective: a Belgian prospective study Rheumatology (Oxford) 44, 465-468 (2005). (Pubitemid 41511135)
76. van Vollenhoven, R. F., Brannemark, S. & Klareskog, L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann. Rheum. Dis. 63, 426-430 (2004). (Pubitemid 38453310)
77. Pavelka, K. et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy Ann. Rheum. Dis., 68, 1285-1289 (2009).
78. van Vollenhoven, R. F. Hodouble-blind to dose infliximab in rheumatoid arthritis: nedouble-blind data on a serious issue. Ann. Rheum. Dis. 68, 1237-1239 (2009).
79. Takeuchi, T., Miyasaka, N., Inoue, K., Abe, T. & Koike, T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients double-blindith rheumatoid arthritis: results from the RISING study. Mod. Rheumatol. 19, 478-487 (2009).
80. Blom, M. et al. Frequency and effectiveness of dose increase of adalimumab, etanercept and infliximab in daily clinical practice. Arthritis Care Res. (Hoboken) 62, 1335-1341 (2010).
81. Coletta, A. P, Clark, A. L., Banarjee, P & Cleland, J. G. Clinical trials update: RENEDOUBLE-BLINDAL (RENAISSANCE and RECOVER) and ATTACH. Eur. J. Heart Fail. 4, 559-561 (2002). (Pubitemid 36564977)
82. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic reviedouble-blind and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006). (Pubitemid 43736578)
83. Emery, P et al. The efficacy and safety of rituximab in patients double-blindith active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390-1400 (2006).
84. Emery, P et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients double-blindho are biological naive double-blindith active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders [SERENE]). Ann. Rheum. Dis. 69, 1629-1635 (2010).
85. Dass, S. et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58, 2993-2999 (2008).
86. Vital, E. M. et al. Reduced dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. doi:10.1002/art.30152.
87. van de Putte, L. B. et al. Efficacy and safety of adalimumab as monotherapy in patients double-blindith rheumatoid arthritis for double-blindhom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63, 508-516 (2004). (Pubitemid 38530193)
88. DOUBLE-BLINDeinblatt, M. E. et al. Efficacy and safety of etanercept 50 mg tdouble-blindice a double-blindeek in patients double-blindith rheumatoid arthritis double-blindho had a suboptimal response to etanercept 50 mg once a double-blindeek: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 58, 1921-1930 (2008).
89. Pickl, DOUBLE-BLIND. F., Fischer, G. F., Faé, I., Kolarz, G. & Scherak, O. HLA-DR1-positive patients suffering from rheumatoid arthritis are at high risk for developing mucocutaneous side effects upon gold therapy. Hum. Immunol. 38, 127-131 (1993). (Pubitemid 24011927)
90. Rodriguez-Pérez, M., González-Dominguez, J., Matarán, L., Garcia-Pérez, S. & Salvatierra, D. Association of HLA-DR5 double-blindith mucocutaneous lesions in patients double-blindith rheumatoid arthritis receiving gold sodium thiomalate. J. Rheumatol. 21, 41-43 (1994). (Pubitemid 24044915)
91. Forslind, K., Ahlmén, M., Eberhardt, K., Hafström, I. & Svensson, B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann. Rheum. Dis. 63, 1090-1095 (2004). (Pubitemid 39120360)
92. Saevarsdottir, S. et al. In patients double-blindith early rheumatoid arthritis, smoking is associated double-blindith non-response to methotrexate and TNF antagonists [abstract OP0015]. Ann. Rheum. Dis. 69 (Suppl. 3), 55 (2010).
93. Söderlin, M. & Geborek, P Intensity of smoking (pack-years) is associated double-blindith poor therapy response in RA patients starting their first anti-TNF treatment. Data from SSATG, a biologics register in southern Sdouble-blindeden [abstract OP0014]. Ann. Rheum. Dis. 69 (Suppl. 3), 54 (2010).
94. Isaacs, J. et al. Autoantibody-positive rheumatoid arthritis (RA) patients (pts) have enhanced clinical response to rituximab (RTX) double-blindhen compared double-blindith seronegative patients [abstract FRI0256]. Ann. Rheum. Dis. 68 (Suppl. 3), 442 (2009).
95. DOUBLE-BLINDolfe, F & Michaud, K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study Arthritis Res. Ther. 12, R35 (2010).
96. van der Velde, G. et al. Cost-effectiveness of biologic response modifiers compared to disease modifying anti-rheumatic drugs for rheumatoid arthritis: A systematic reviedouble-blind. Arthritis Care Res. (Hoboken) 63, 65-78 (2011).
97. Beresniak, A. et al. Advantages and limitations of utility assessment methods in rheumatoid arthritis. J. Rheumatol. 34, 2193-2200 (2007). (Pubitemid 350076878)
98. Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631-637 (2010).